Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.744,64
1,36%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Coherus BioSciences Inc (CHRS) Coherus BioSciences Inc (CHRS) Notizie

Coherus BioSciences Inc

CHRS
2,25
0,08 (3,69%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
01/5/202422:30GLOBECoherus to Report First Quarter 2024 Financial Results on..
24/4/202416:02GLOBECoherus Announces Presentation at the 2024 American Society..
08/4/202414:30GLOBECoherus Presents Preclinical Data for CHS-1000, a Novel..
13/3/202421:01GLOBECoherus BioSciences Reports Fourth Quarter, Full Year 2023..
05/3/202422:01GLOBECoherus to Report Fourth Quarter and Full Year 2023..
04/3/202412:22EDGAR2Form 8-K - Current report
04/3/202407:00GLOBECoherus Completes Divestiture of Ophthalmology Franchise
23/2/202423:33GLOBECoherus BioSciences Announces New Employment Inducement..
22/2/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202423:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/2/202422:59EDGAR2Form 8-K - Current report
21/2/202414:30GLOBECoherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and..
05/2/202414:09EDGAR2Form 8-K - Current report
05/2/202414:00GLOBECoherus Amends Term Loan Agreement with Pharmakon Advisors,..
24/1/202402:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202414:01EDGAR2Form 8-K - Current report
22/1/202407:59DJNSandoz to Acquire Cimerli Business from Coherus for $170..
22/1/202407:15GLOBECoherus Announces Agreement to Divest Ophthalmology..
18/1/202422:05GLOBECoherus Presents Positive Phase 2 Clinical Data on..
10/1/202403:41EDGAR2Form 8-K - Current report
10/1/202403:39EDGAR2Form 8-K - Current report
10/1/202401:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202423:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202414:00PRNUSINOVIO and Coherus Announce Clinical Collaboration to..
03/1/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:00GLOBECoherus BioSciences Management to Present at the 42nd Annual..
02/1/202414:29GLOBECoherus Announces U.S. Launch of LOQTORZI™
27/12/202315:15APSAnother Biotech Massively Outperforming Broader Equities
27/12/202312:08IHMARKETNEWSWall Street Highlights: Apple Appeals Watch Ban, Tesla to..
26/12/202322:43DJNCoherus BioSciences Gets FDA OK for Udenyca Injector
26/12/202322:01GLOBECoherus Announces FDA Approval of UDENYCA ONBODY™, a Novel..
22/12/202323:00GLOBECoherus BioSciences Announces New Employment Inducement..
15/12/202322:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202322:13EDGAR2Form 8-K - Current report
11/12/202314:30GLOBECoherus Announces Updated NCCN Clinical Practice Guidelines..
07/12/202323:55GLOBECoherus BioSciences Announces CFO Transition Plans
07/12/202323:16EDGAR2Form 8-K - Current report
06/12/202310:00GLOBECoherus Presents Phase 1/2 Clinical Data on Casdozokitug, a..
28/11/202317:16GLOBECoherus and Junshi Biosciences Announce Publication of..
27/11/202322:03EDGAR2Form 8-K - Current report
13/11/202312:07EDGAR2Form 8-K/A - Current report: [Amend]
06/11/202322:35EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202322:31EDGAR2Form 8-K - Current report
06/11/202322:07GLOBECoherus BioSciences Reports Third Quarter 2023 Financial..
06/11/202312:07EDGAR2Form 8-K/A - Current report: [Amend]
03/11/202313:30GLOBECoherus Presents Data from Next-generation Immuno-oncology..
03/11/202301:00GLOBECoherus BioSciences to Participate at Upcoming November..
Apertura: 2,20 Min: 2,19 Max: 2,3219
Chiusura: 2,17

La tua Cronologia

NASDAQ
CHRS
Coherus BioSciences
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network